Fluctuating expression of miR-584 in primary and high-grade gastric cancer
A recent study found that H. Pylori infection raises levels of a particular miRNA, which could be used as a biomarker for... Read More
Periodontal Disease, Tooth Loss Linked to Esophageal, Gastric Cancer
Harvard researchers found that people with a history of dental problems also face an increased risk of esophageal and gastric cancer.
Nivolumab Demonstrates Efficacy in Preliminary Data for Gastric Cancer
Gastric cancer patients taking the immune-boosting drug Opdivo in a clinical trial had a disease control rate of 39%, according to a... Read More
Biosimilar Trastuzumab Effective in Triplet Regimen for Gastric Cancer
A biosimilar version of Herceptin taken in combination with chemo and the immune-boosting drug Keytruda reduced tumor size in a clinical trial... Read More
Drug-Drug Interactions to Avoid in Patients With GI Cancer
People with HER2-positive gastric cancer should not take proton pump inhibitors for heartburn while they are undergoing treatment, recent studies have found.
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers
Adding Herceptin to chemotherapy in gastric cancer patients with ERBB2-positive tumors produced an 85% response rate.
The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target
Tumor-associated macrophages represent an exciting new target in the development of treatments for gastric cancer.
RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
RemeGen announced a 24% response rate in a clinical trial of its antibody drug conjugate RC48 in patients with HER-2 positive gastric... Read More
MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
MacroGenics received orphan drug designation from the FDA for its investigational gastric cancer drug margetuximab.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Gastric cancer patients treated with Enhertu in a recent study had favorable response rates, survival and duration of response as compared to... Read More